Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

531
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
531
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

459
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
459
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

507
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
507
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

384
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
384
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

565
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
565
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

339
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
339

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic markers enhance mortality prediction in heart failure.

European heart journal·2026
Same author

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Future oncology (London, England)·2026
Same author

Country-specific differences in the association between obesity risk factors in two high-income countries: a cross-sectional analysis from the Prospective Urban Rural Epidemiology (PURE) study.

BMC public health·2026
Same author

Canagliflozin is a novel androgen receptor pathway inhibitor for castrate-sensitive and castrate-resistant prostate cancer.

Cancer letters·2026
Same author

Genetic testing practices among specialist physicians who treat prostate cancer: Updated survey of Canadian practitioners.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2026
Same author

Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.

Breast cancer research and treatment·2026

Related Experiment Video

Updated: Jan 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K

Reversible Cabozantinib-Induced Cardiomyopathy.

Muhammad Alhussein1, Sebastien J Hotte2, Darryl P Leong3

  • 1The Division of Cardiology, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

The Canadian Journal of Cardiology
|April 3, 2019
PubMed
Summary

Cabozantinib, a cancer drug, can cause reversible heart failure. This case report highlights a potential cardiac side effect of this tyrosine kinase inhibitor in patients with kidney cancer.

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.4K

Related Experiment Videos

Last Updated: Jan 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.4K

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Cabozantinib is a tyrosine kinase inhibitor targeting VEGFR, MET, RET, and AXL.
  • It is approved for advanced thyroid and kidney cancers and under investigation for other malignancies.
  • Cardiac toxicities are a known concern with some tyrosine kinase inhibitors.

Observation:

  • A 70-year-old man with metastatic renal cell carcinoma developed heart failure.
  • The patient was receiving treatment with cabozantinib.
  • Cardiac function improved after discontinuation of the drug.

Findings:

  • This case presents reversible cardiomyopathy associated with cabozantinib therapy.
  • It is one of the first reported instances of cabozantinib-induced cardiomyopathy.
  • The findings suggest a potential cardiotoxic mechanism of cabozantinib.

Implications:

  • Clinicians should monitor for cardiac function in patients treated with cabozantinib.
  • Early recognition and management of cabozantinib-induced heart failure may improve patient outcomes.
  • Further research is warranted to elucidate the mechanisms of cabozantinib cardiotoxicity.